SHANGHAI: Beijing’s targeting of British pharmaceutical giant GlaxoSmithKline (GSK) in a high-profile bribery probe is a reminder of the risks foreign companies face when seeking the huge rewards of China’s market, analysts say.

Authorities have detained four Chinese GSK executives on allegations that employees used nearly $500 million in bribes to boost sales.

Premium + Digital Edition

Ad-free access


P 80 per month
(billed annually at P 960)
  • Unlimited ad-free access to website articles
  • Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)

TRY FREE FOR 14 DAYS
See details
See details